Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × OTHER × lanreotide × Clear all

Phase

Phase 2 6 Phase 4 4 Phase 3 2 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Magnetic Resonance Spectroscopy 51 Cyclophosphamide 37 pembrolizumab 32 Radiotherapy 28 Biopsy 24 fludarabine 23 Nivolumab 20 Metformin 20 Fluorodeoxyglucose F18 19 Specimen Handling 18 Bevacizumab 18 Temozolomide 13 Radiosurgery 13 Cisplatin 12 durvalumab 11 Letrozole 11 Dexamethasone 11 Carboplatin 11 gallium 68 PSMA-11 10 Paclitaxel 10 Fluorouracil 10 X-Rays 9 Standard of Care 9 Radiation 9 Ipilimumab 9 Immunotherapy, Adoptive 9 Gemcitabine 9 Etoposide 9 Doxorubicin 9 olaparib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡